| Genotype‐Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review M Kasten, C Hartmann, J Hampf, S Schaake, A Westenberger, ... Movement Disorders 33 (5), 730-741, 2018 | 316 | 2018 |
| Mitochondrial damage-associated inflammation highlights biomarkers in PRKN/PINK1 parkinsonism M Borsche, IR König, S Delcambre, S Petrucci, A Balck, N Brüggemann, ... Brain 143 (10), 3041-3051, 2020 | 148 | 2020 |
| Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis L Tönges, R Günther, M Suhr, J Jansen, A Balck, KA Saal, E Barski, ... Glia 62 (2), 217-232, 2014 | 131 | 2014 |
| Complications of nasal and pharyngeal swabs: a relevant challenge of the COVID-19 pandemic? B Föh, M Borsche, A Balck, S Taube, J Rupp, C Klein, A Katalinic European Respiratory Journal 57 (4), 2021 | 81 | 2021 |
| Genotype–phenotype relations in primary familial brain calcification: systematic MDSGene review A Balck, S Schaake, NS Kuhnke, A Domingo, H Madoev, J Margolesky, ... Movement Disorders 36 (11), 2468-2480, 2021 | 64 | 2021 |
| Primary familial brain calcifications: genetic and clinical update A Westenberger, A Balck, C Klein Current opinion in neurology 32 (4), 571-578, 2019 | 56 | 2019 |
| Rho Kinase Inhibition with Fasudil in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis—Symptomatic Treatment Potential after Disease Onset R Günther, A Balck, JC Koch, T Nientiedt, M Sereda, M Bähr, P Lingor, ... Frontiers in pharmacology 8, 17, 2017 | 47 | 2017 |
| Utility and implications of exome sequencing in early‐onset Parkinson's disease J Trinh, K Lohmann, H Baumann, A Balck, M Borsche, N Brüggemann, ... Movement Disorders 34 (1), 133-137, 2019 | 42 | 2019 |
| One-year surveillance of SARS-CoV-2 transmission of the ELISA cohort: A model for population-based monitoring of infection risk C Klein, M Borsche, A Balck, B Föh, J Rahmöller, E Peters, J Knickmann, ... Science advances 8 (15), eabm5016, 2022 | 25 | 2022 |
| Coffee, smoking and aspirin are associated with age at onset in idiopathic Parkinson’s disease C Gabbert, IR König, T Lüth, B Kolms, M Kasten, EJ Vollstedt, A Balck, ... Journal of neurology 269 (8), 4195-4203, 2022 | 24 | 2022 |
| Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson’s disease study A Westenberger, V Skrahina, T Usnich, C Beetz, EJ Vollstedt, BH Laabs, ... Brain 147 (8), 2652-2667, 2024 | 19 | 2024 |
| Discordant monozygotic parkinson disease twins: Role of mitochondrial integrity M Dulovic‐Mahlow, IR König, J Trinh, SH Diaw, PP Urban, E Knappe, ... Annals of Neurology 89 (1), 158-164, 2021 | 14 | 2021 |
| Adult-onset ataxia or developmental disorder with seizures: two sides of missense changes in CACNA1A A Balck, H Hanssen, Y Hellenbroich, K Lohmann, A Münchau Journal of Neurology 264, 1520-1522, 2017 | 14 | 2017 |
| Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19 M Borsche, D Reichel, A Fellbrich, AS Lixenfeld, J Rahmöller, EJ Vollstedt, ... Neurological research and practice 3, 1-3, 2021 | 12 | 2021 |
| α‐Synuclein Pathology in PRKN‐Linked Parkinson's Disease: New Insights from a Blood‐Based Seed Amplification Assay A Kluge, M Borsche, L Streubel‐Gallasch, T Gül, S Schaake, A Balck, ... Annals of Neurology, 2024 | 10 | 2024 |
| The sooner, the later–Delayed diagnosis in Parkinson's disease due to Parkin mutations M Borsche, A Balck, M Kasten, K Lohmann, C Klein, N Brüggemann Parkinsonism & Related Disorders 65, 284-285, 2019 | 9 | 2019 |
| In Vivo Investigation of Glucose Metabolism in Idiopathic and PRKN‐Related Parkinson's Disease M Borsche, A Märtens, P Hörmann, T Brückmann, K Lohmann, S Tunc, ... Movement Disorders 38 (4), 697-702, 2023 | 8 | 2023 |
| Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study–a prospective population-based cohort study A Balck, B Föh, M Borsche, J Rahmöller, EJ Vollstedt, F Waldeck, ... BMC Public Health 22 (1), 1305, 2022 | 7 | 2022 |
| Metabolic markers distinguish COVID-19 from other intensive care patients and show potential to stratify for disease risk F Schmelter, B Foeh, A Mallagaray, J Rahmoeller, M Ehlers, S Lehrian, ... medRxiv, 2021.01. 13.21249645, 2021 | 7 | 2021 |
| A Novel Frameshift CACNA1A Mutation Causing Episodic Ataxia Type 2 A Balck, S Tunc, J Schmitz, R Hollstein, FJ Kaiser, N Brüggemann The Cerebellum 17, 504-506, 2018 | 7 | 2018 |
